Evaluation of the Effects of Calcitriol's in the Neurological Symptoms of Friedreich's Ataxia Patients

NCT ID: NCT04801303

Last Updated: 2023-10-23

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Total Enrollment

20 participants

Study Classification

INTERVENTIONAL

Study Start Date

2021-08-25

Study Completion Date

2023-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Friedreich's Ataxia (FA) is an autosomal recessive disease the mutation of which leads to a deficiency of a protein called frataxin, which is responsible for the symptoms of the disease. It is assumed that inducing an increase in the production of frataxin could reverse part of the disease's symptoms.

Several treatments with drugs that raise frataxin levels have been tested, but they have either have not given the expected result or have induced intolerable side effects. The IRBLleida (Institut de Recerca Biomèdica de Lleida Fundació Dr. Pifarré) team has shown that calcitriol can increase the production of frataxin up to 2.5 to 3 times, a higher proportion than any of the drugs previously tested. For that reason, the next step in our research would be to check the effects of this drug (Calcitriol 0.25mcg/24h for a year) in patients with FA. On the other hand, calcitriol, the active form of vitamin D, is a drug with a very low rate of adverse effects that has been used for decades. Therefore, it is a drug with a very well established tolerability. The results of the present study, if positive, would lead to the organization of trials at a larger scale, and they would allow the use of an effective treatment for patients with FA.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Friedreich's Ataxia (FA) is a recessive hereditary disease due to GAA (Guanine-Adenosine-Adenosine) triplet repeats in the FXN (Frataxin) gene. This gene codifies for the frataxin protein, the lack of which produces the neurological and cardiac symptoms.

The exact mechanisms why the lack of frataxin produces the disease aren't well understood, but it is known that frataxin is located in the mitochondria. Calcitriol synthesis, a mitochondrial process, could be impaired in FA due the reduction of CYP27B1 (Cytochrome P450, family 27, subfamily B, member 1) and Fdx1.

Because of some studies have shown that Calcitriol (the active form of D Vitamin) could raise the frataxin levels, it could have a beneficial effect in patients with FA.

Description of the trial: to assess the effect of Calcitriol 0.25mcg/24h for a year in the neurological function of FA patients.

Main objective of the trial: to evaluate the effects of Calcitriol in the neurological symptoms of patients with FA.

The second objectives of the trial are:

1. To evaluate the safety and the risk of hypercalcemia with the treatment with low dosis of Calcitriol (0.25mcg of Calcitriol every 24h) in patients with FA.
2. To measure de change in the Frataxin's levels during the treatment with Calcitriol.
3. To evaluate the effects of Calcitriol in the daily life activities and the life quality of the patients with FA.

Sample size: The number of participants needed to compleat the trial is 20. Duration: The duration of the trial is one year

Procedure:

* Before taking part in the study, it will be ensured that participants fulfill all the inclusion criteria with a detailed questionnaire.
* During the clinical trial the following test will be done: 4 electrocardiogram, 5 blood analysis to control de risk of hypercalcemia and to measure the frataxin's levels, and 3 full neurological examinations.

Post trial treatment details:

The patients who wish to continue with the treatment will be allowed to do so, at least until the results of the comparison of the basal neurological evaluation with the second and the final neurological evaluation are obtained.

If the results are positive, the treatment will be continued with regular blood tests controls.

If the results don't demonstrate a statistically significant effect, the treatment will be interrupted in all patients.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Friedreich Ataxia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Evaluate the effects of Calcitriol 0.25mcg/24h administered during a year in the neurological symptoms of patients with Friedreich's Ataxia
Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Friedreich's Ataxia patients

Friedreich's Ataxia patients that will receive treatment with Calcitrol 0.25mcg/24h for a year.

During the clinical trial:

* The effects of Calcitriol in the neurological symptoms of Friedreich's Ataxia patients will be evaluated before starting the treatment and after a year. The following scales will be used: SARA scale, 9-Hole Peg test, 8 meters walking test, PATA velocity test and Quality of life test with the SF36 questionnaire.
* The changes in the Frataxin's levels during the treatment with Calcitriol will be measured: before starting the treatment, and after fifteen days, 4 months, 8 months and 12 months of the treatment.

Group Type EXPERIMENTAL

Calcitriol

Intervention Type DRUG

Administration of Calcitrol 0.25mcg/24h for a year in Friedreich's Ataxia patients (n=20)

Blood analysis for frataxin's level measurement

Intervention Type OTHER

1. Five blood analysis in Friedreich's Ataxia patients: before starting the treatment, and after fifteen days, 4 months, 8 months and 12 months of the treatment.
2. To validate the Frataxin's levels measurement, a blood analysis will also be done in two kind of controls for every Friedreich's Ataxia patient, only once at the beginning of the trial.

The control groups will be composed by:

* Heterozygous Ataxia's Friedreich controls (a close relative of the patient, either a heterozygous sibling or one of the parents)
* Age- and gender-matched controls (supposedly non-heterozygous).

Blood analysis for hypercalcemia's control

Intervention Type DIAGNOSTIC_TEST

Five blood analysis in Friedreich's Ataxia patients for monitoring the hypercalcemia risk (with measurement of Calcium, D Vitamin, renal function, albumin, protein, phosphate, sodium and potassium) Before starting the treatment, and after fifteen days, at 4 months, 8 months and 12 months of the treatment.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Calcitriol

Administration of Calcitrol 0.25mcg/24h for a year in Friedreich's Ataxia patients (n=20)

Intervention Type DRUG

Blood analysis for frataxin's level measurement

1. Five blood analysis in Friedreich's Ataxia patients: before starting the treatment, and after fifteen days, 4 months, 8 months and 12 months of the treatment.
2. To validate the Frataxin's levels measurement, a blood analysis will also be done in two kind of controls for every Friedreich's Ataxia patient, only once at the beginning of the trial.

The control groups will be composed by:

* Heterozygous Ataxia's Friedreich controls (a close relative of the patient, either a heterozygous sibling or one of the parents)
* Age- and gender-matched controls (supposedly non-heterozygous).

Intervention Type OTHER

Blood analysis for hypercalcemia's control

Five blood analysis in Friedreich's Ataxia patients for monitoring the hypercalcemia risk (with measurement of Calcium, D Vitamin, renal function, albumin, protein, phosphate, sodium and potassium) Before starting the treatment, and after fifteen days, at 4 months, 8 months and 12 months of the treatment.

Intervention Type DIAGNOSTIC_TEST

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Rocaltrol

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients with Friedreich's Ataxia and confirmed genetic diagnosis with:

* Two pathological GAA triplet repeats in the gen FXN
* One pathological GAA triplet repeat and one point mutation in the gen FXN
* Patients between 16 and 65 years of age.
* To keep the walking ability, although an external aid is needed.
* Women with confirmed genetic diagnosis must use an effective contraceptive method during the trial.

Exclusion Criteria

* Any neurological or other kind of disease that could interfere in the trial according to the investigator judgement.
* Severe visual loss.
* Severe auditory loss.
* Cognitive decline\*.

* Dementia or affective-cognitive cerebellar syndrome.
* Serious psychiatric illness during the six previous months of the trial inclusion.
* Substance abuse during the six previous months of the trial inclusion.
* Severe drug allergy.
* Cardiac disease:

* Ejection fraction \<40% \[N: 50-70%\]
* Heart failure \> 2 from NYHA (New York Heart Association) criteria.
* Significant valvular heart disease.
* Symptomatic coronary artery disease.
* Cardiac arrhythmia with hemodynamic compromise (atrial fibrillation).
* Prolonged immobilisation
* Use of research drugs during the 30 previous days of the trial inclusion.
* Concomitant treatment with digoxin, thiazide diuretics, cholestyramine, corticoids, laxatives with magnesium, barbiturates and antiepileptic drugs. Use of Calcium or Vitamin D drugs during the 30 previous days of the trial inclusion.
* Legally or mentally incapacitated person.
* In women:

* Positive pregnancy test.
* Maternal breastfeeding.
* Blood test alteration:

* Hypercalcemia.
* Elevated creatinine.
Minimum Eligible Age

16 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Institut de Recerca Biomèdica de Lleida

OTHER

Sponsor Role collaborator

Universitat de Lleida

OTHER

Sponsor Role collaborator

Institut d'Investigació Biomèdica de Girona Dr. Josep Trueta

OTHER

Sponsor Role collaborator

Berta Alemany

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Berta Alemany

Principal Investigator

Responsibility Role SPONSOR_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Berta Alemany Perna

Role: PRINCIPAL_INVESTIGATOR

Hospital Universitari Josep Trueta/Hospital Santa Caterina, Girona/Salt, Spain

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Hospital Santa Caterina/Parc Martí i Julià

Salt, , Spain

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Spain

References

Explore related publications, articles, or registry entries linked to this study.

Britti E, Delaspre F, Sanz-Alcazar A, Medina-Carbonero M, Llovera M, Purroy R, Mincheva-Tasheva S, Tamarit J, Ros J. Calcitriol increases frataxin levels and restores mitochondrial function in cell models of Friedreich Ataxia. Biochem J. 2021 Jan 15;478(1):1-20. doi: 10.1042/BCJ20200331.

Reference Type RESULT
PMID: 33305808 (View on PubMed)

Provided Documents

Download supplemental materials such as informed consent forms, study protocols, or participant manuals.

Document Type: Study Protocol and Statistical Analysis Plan

View Document

Document Type: Informed Consent Form: Healthy control informed consent form

View Document

Document Type: Informed Consent Form: Healthy control informed consent form

View Document

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2020-001092-32

Identifier Type: EUDRACT_NUMBER

Identifier Source: secondary_id

IdIBGI

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Iron-Chelating Therapy and Friedreich Ataxia
NCT00224640 COMPLETED PHASE1/PHASE2
Idebenone to Treat Friedreich's Ataxia
NCT00229632 COMPLETED PHASE2
Methylprednisolone Treatment of Friedreich Ataxia
NCT02424435 COMPLETED EARLY_PHASE1